Jimicsiga joogtada ahi wuxuu yareeyaa halista 7 nooc oo kansar ah

Jimicsiga joogtada ah wuxuu yareeyaa halista 7 nooc oo kansar ah oo kala duwan ayaa lagu ogaaday cilmi-baaris ay sameeyeen bulshada kansarka ee Mareykanka, Machadka Kansarka Qaranka & Harvard THChan Iskuulka Caafimaadka Dadweynaha.

La qaybso Post this

Daraasad lagu sameeyay dalka Mareykanka ayaa lagu ogaaday in jimicsiga joogtada ah uu yareeyo halista 7 nooc oo kansar ah. Daraasadan waxaa sameeyay Cancer American Society, Machadka Kansarka Qaranka, & Harvard T.Chan Iskuulka caafimaadka dadweynaha. Daraasaddan waxaa lagu daabacay Joornaalka Oncology Clinical.

Ujeedada daraasadda

Si loo go'aamiyo in xaddiga lagu taliyay ee jimicsiga-wakhtiga firaaqada ah (ie, 7.5-15 shaqo u dhiganta dheef-shiid kiimikaad [MET] saacadood / usbuucii) ay la xiriiraan halista kansarka oo hooseeya, sharrax qaabka xiriirka ka-jawaab-celinta qiyaasta, iyo sahaminta ururada leh dhexdhexaad- iyo firfircoonaan xoog leh.

Natiijada daraasadda

Wadarta kaqeybgalayaasha 755,459 (da'da dhexdhexaadka ah, 62 sano [xaddiga, 32-91 sano]; 53% dheddig) ayaa la raacay 10.1 sano, iyo 50,620 kansar dhacdo. Kaqeybgalka xaddiga waxqabadka lagu taliyay (7.5-15 MET saacadood / usbuucii) wuxuu la xiriiray halista tirakoobka ee aadka u hooseysa ee 7 oo ka mid ah 15 noocyada kansarka ee la darsay, oo ay ku jiraan xiidanka (8% -14% khatarta ragga ka hooseysa), naaska (6% -10% khatarta hoose), endometrial (10% -18% khatarta hoose), kilyaha (11% -17% khatarta hoose), myeloma (14% -19% khatarta hoose), beerka (18% -27% khatarta hoose) , iyo non-Hodgkin lymphoma (11% -18% khatarta hoose ee haweenka). Jawaabta qaddarku waxay ahayd qaab qaab ahaan u eg kalabar ururada iyo kuwa aan toos ahayn kuwa kale. Natiijooyinka jimicsi dhexdhexaad ah iyo xoog-firfircoon oo jimicsi-jimicsi ah ayaa la isku daray. Isku hagaajinta tirada guud ee jirka ayaa meesha ka saartay xiriirkii kansarka endometrial laakiin wuxuu saameyn xadidan ku yeeshay noocyada kale ee kansarka.
Jimicsiga joogtada ahi wuxuu si gaar ah ugu xirnaa:

  • 8% khatarta hoose ee kansarka mindhicirka ee ragga 7.5 MET saacadood toddobaadkii iyo 14% khatarta hoose ee 15 MET saacadood toddobaadkii.
  • 6% khatarta hoose ee kansarka naasaha ee haweenka 7.5 MET saacadood todobaadkii iyo 10% khatarta hoose ee 15 MET saacadood toddobaadkii
  • Khatarta 10% ee khatarta kansarka endometrial ee haweenka saacadaha 7.5 MET asbuucii iyo 18% khatarta hoose ee saacadaha 15 MET usbuucii
  • Khatarta 11% ee kansarka kalyaha 7.5 MET saacadood usbuucii iyo 17% khatarta hooseysa 15 saacadood oo MET asbuucii
  • Khatarta 14% hooseysa ee myeloma badan saacadaha 7.5 MET usbuucii iyo 19% khatarta hoose ee saacadaha 15 MET usbuucii
  • 18% khatarta hoose ee kansarka beerka 7.5 MET saacadood todobaadkii iyo 27% khatarta hoose ee 15 MET saacadood todobaadkii.
  • Khatarta 11% ee khatarta ah non-Hodgkin lymphoma ee haweenka saacadaha 7.5 MET asbuucii iyo 18% khatarta hoose ee saacadaha 15 MET usbuucii

Marka waa run oo jimicsiga joogtada ahi waa hub aad u awood badan oo looga hortago kansarka. Noocyada kansarka ee la xaqiijiyay ee laga hortagi karo waa kansarka mindhicirka weyn, kansarka naasaha, kansarka Endometrial, kansarka kilyaha, Myeloma badan, kansarka beerka, Myeloma, Non-Hodgkin Lymphoma.
Kaliya adoo socda 30 daqiiqo maalintii ayaa yareyneysa halistaas si aad ah.

Ku soo Dhawo Wargeyskayaga

Hel wax cusub oo waligaa ha ka maqnaan blog ka Cancerfax

Inbadan Oo La Baadho

Fahamka Cytokine Release Syndrome: Sababaha, Calaamadaha, iyo Daaweynta
Daaweynta T-Cell-ka Baabuurka

Fahamka Cytokine Release Syndrome: Sababaha, Calaamadaha, iyo Daaweynta

Cytokine Release Syndrome (CRS) waa falcelin habdhiska difaaca oo inta badan ka dhasha daawaynta qaarkood sida immunotherapy ama daawaynta unugga CAR-T. Waxay ku lug leedahay sii-deynta xad-dhaafka ah ee cytokines, taasoo keenta calaamado u dhexeeya qandho iyo daal ilaa dhibaatooyin nafta halis gelin kara sida dhaawaca xubnaha. Maareyntu waxay u baahan tahay kormeer taxadar leh iyo xeelado faragelineed.

Doorka dhakhaatiirta caafimaadka ee guusha daaweynta unugyada CAR T
Daaweynta T-Cell-ka Baabuurka

Doorka dhakhaatiirta caafimaadka ee guusha daaweynta unugyada CAR T

Dhakhaatiirta caafimaadka ayaa door muhiim ah ka ciyaara guusha daaweynta CAR T-cell iyaga oo hubinaya daryeelka bukaanka ee aan joogtada ahayn inta lagu jiro habka daaweynta. Waxay bixiyaan taageero muhiim ah inta lagu jiro gaadiidka, la socodka calaamadaha muhiimka ah ee bukaanka, iyo maamulida waxqabadyada caafimaadka degdega ah haddii ay dhibaatooyin soo baxaan. Jawaabtooda degdega ah iyo daryeelka khabiirku waxay gacan ka geystaan ​​​​badbaadada guud iyo waxtarka daaweynta, fududeynta kala-guurka fudud ee u dhexeeya goobaha daryeelka caafimaadka iyo hagaajinta natiijooyinka bukaanka ee muuqaalka adag ee daaweynta gacanta ee sare.

Ma u baahan tahay caawimaad? Kooxdayadu waxay diyaar u yihiin inay ku caawiyaan.

Waxaan u rajeynaynaa caafimaad deg-deg ah mid aad jeceshahay iyo mid kuu dhow.

Bilow sheekada
Waxaan nahay Online! Nala hadal!
Sawir koodka
Hello,

Ku soo dhawoow CancerFax!

CancerFax waa madal horudhac ah oo u heellan in lagu xidho shakhsiyaadka wajahaya kansarka heerka sare ee daawaynta unugyada sida CAR T-Cell therapy, daawaynta TIL, iyo tijaabooyinka caafimaad ee adduunka oo dhan.

Nala soo socodsii waxaan kuu qaban karno.

1) Daaweynta kansarka ee dibadda?
2) CAR T-Cell therapy
3) Tallaalka kansarka
4) La-talinta fiidiyowga ee khadka tooska ah
5) daawaynta Proton